Head and neck cancer usually develops in the squamous cells that line the moist, mucosal surfaces inside the salivary glands, and head and neck. Alcohol use, tobacco use are major risk factors associated with the head and neck cancer. The other risk factors include human papillomavirus (HPV) infections, oral health, radiation exposure, preserved or salty foods, occupational exposure, ancestry, Epstein-Barr virus infection, and others. According to the American Society of Clinical Oncology (ASCO), head and neck cancer accounted for around 3% of all cancers in the U.S., in 2016. Head and neck cancers are more than twice as common among men as compared to women. Luzitin SA is in the process of developing Redaporfin as a photosensitiser for the treatment of head and neck cancer. Some of the companies having a pipeline of head and neck cancer include Pfizer Inc., AstraZeneca plc, Luzitin SA and others.
The report provides a comprehensive understanding of the pipeline activities covering all the drug candidates under the various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities, including information about clinical results, designations, collaborations, licencing, grants, technology and others.